Trials / Recruiting
RecruitingNCT04643106
Comparison of Hemostatic Agent to Suture in Terms of Hemostatic Function and Preservation of Ovarian Function
A Multi-center, Randomized, Investigator-initiated Trial to Evaluate the Efficacy of PRreservation of ovArian Function, Hemostasis, and sAfety of a Hemostatic Agent Versus Suturing During Laparoscopic Ovarian Cystectomy for Endometrioma
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- Female
- Age
- 19 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the efficacy of preservation of ovarian function, hemostasis, and safety of a hemostatic agent versus suturing during laparoscopic ovarian cystectomy for ovarian endometriosis.
Detailed description
In women with endometrioma who plan to undergo laparoscopic ovarian cystectomy, surgical technique can influence postoperative ovarian function because of removal of normal ovarian tissue with ovarian cyst and damage to ovarian tissue during bleeding control after stripping of endometrioma. This study is designed to compare hemostatic sealant to suturing in terms of hemostatic function, safety and preservation of ovarian function. Ovarian function of all patients will be evaluated on pre op, post op 12 weeks, post op 48 weeks by measuring AMH and ovarian volume. And Hemostatic function will be evaluated by measuring serum hemoglobin, blood loss during operation, etc.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Hemostatic agent (EVICEL®) application during laparoscopic ovarian cystectomy | During laparoscopic ovarian cystectomy, bleeding will be controlled by using a hemostatic agent (EVICEL®) |
| PROCEDURE | suturing with barbed sutures during laparoscopic ovarian cystectomy | During laparoscopic ovarian cystectomy, suturing of ovarian inner surface will be conducted to stop bleeding |
Timeline
- Start date
- 2021-02-25
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
- First posted
- 2020-11-24
- Last updated
- 2023-06-26
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04643106. Inclusion in this directory is not an endorsement.